INTS vs. CGEN, EDIT, CHRS, TIL, NMRA, LXEO, ALEC, SNTI, CCCC, and ZURA
Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include Compugen (CGEN), Editas Medicine (EDIT), Coherus BioSciences (CHRS), Instil Bio (TIL), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), Alector (ALEC), Senti Biosciences (SNTI), C4 Therapeutics (CCCC), and Zura Bio (ZURA). These companies are all part of the "biological products, except diagnostic" industry.
Intensity Therapeutics, Inc. Common stock vs.
Compugen (NASDAQ:CGEN) and Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.
12.2% of Compugen shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics, Inc. Common stock shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 18.6% of Intensity Therapeutics, Inc. Common stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Intensity Therapeutics, Inc. Common stock has lower revenue, but higher earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Intensity Therapeutics, Inc. Common stock, indicating that it is currently the more affordable of the two stocks.
Compugen has a net margin of 2.67% compared to Intensity Therapeutics, Inc. Common stock's net margin of 0.00%. Compugen's return on equity of 2.62% beat Intensity Therapeutics, Inc. Common stock's return on equity.
Compugen currently has a consensus price target of $4.00, suggesting a potential upside of 170.27%. Intensity Therapeutics, Inc. Common stock has a consensus price target of $8.50, suggesting a potential upside of 1,417.86%. Given Intensity Therapeutics, Inc. Common stock's stronger consensus rating and higher probable upside, analysts clearly believe Intensity Therapeutics, Inc. Common stock is more favorable than Compugen.
Compugen received 299 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 100.00% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 64.24% of users gave Compugen an outperform vote.
Compugen has a beta of 3.19, suggesting that its share price is 219% more volatile than the S&P 500. Comparatively, Intensity Therapeutics, Inc. Common stock has a beta of 4.03, suggesting that its share price is 303% more volatile than the S&P 500.
In the previous week, Intensity Therapeutics, Inc. Common stock had 4 more articles in the media than Compugen. MarketBeat recorded 5 mentions for Intensity Therapeutics, Inc. Common stock and 1 mentions for Compugen. Intensity Therapeutics, Inc. Common stock's average media sentiment score of 1.89 beat Compugen's score of 1.87 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the news media.
Summary
Intensity Therapeutics, Inc. Common stock beats Compugen on 10 of the 18 factors compared between the two stocks.
Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intensity Therapeutics, Inc. Common stock Competitors List
Related Companies and Tools
This page (NASDAQ:INTS) was last updated on 4/27/2025 by MarketBeat.com Staff
